Published in Ann Oncol on September 11, 2012
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol (2015) 1.67
First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer (2013) 1.36
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives. Oncotarget (2015) 1.31
Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol (2015) 1.15
Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC). Target Oncol (2013) 1.13
Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations. J Thorac Oncol (2014) 1.08
Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. J Thorac Dis (2013) 1.03
Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies. Transl Lung Cancer Res (2015) 0.99
Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors. PLoS One (2013) 0.98
Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer-the Holy Grail in cancer treatment? Transl Lung Cancer Res (2015) 0.95
Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. Br J Cancer (2015) 0.91
Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK. Drugs (2015) 0.90
Efficacy of EGFR tyrosine kinase inhibitors in non-small-cell lung cancer patients with/without EGFR-mutation: evidence based on recent phase III randomized trials. Med Sci Monit (2014) 0.90
Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment. Cancer Manag Res (2013) 0.88
EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence. Int J Clin Exp Pathol (2013) 0.87
EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer. Drug Des Devel Ther (2014) 0.86
Modeling the relationship between progression-free survival and overall survival: the phase II/III trial. Clin Cancer Res (2013) 0.86
Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3. Cancer Sci (2015) 0.86
Targeted therapies in non-small cell lung carcinoma: what have we achieved so far? Ther Adv Med Oncol (2013) 0.86
Clinical impact of the new IASLC/ATS/ERS lung adenocarcinoma classification for chest surgeons. Surg Today (2014) 0.85
Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients. Transl Lung Cancer Res (2013) 0.85
EGFR inhibition in non-small cell lung cancer: current evidence and future directions. Biomark Res (2013) 0.85
Selection of chemotherapy for non-small cell lung cancer is facilitated by new therapeutic strategies. Int J Clin Exp Med (2014) 0.84
Treatment of advanced squamous cell carcinoma of the lung: a review. Transl Lung Cancer Res (2015) 0.84
Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells. Int J Clin Exp Pathol (2015) 0.84
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol (2017) 0.83
Emerging options for the management of non-small cell lung cancer. Clin Med Insights Oncol (2013) 0.82
Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and Future. Front Oncol (2014) 0.82
Sequential treatment of tyrosine kinase inhibitors and chemotherapy for EGFR-mutated non-small cell lung cancer: a meta-analysis of Phase III trials. Onco Targets Ther (2013) 0.82
Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib. BioDrugs (2015) 0.82
Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients. Jpn J Clin Oncol (2016) 0.81
Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line. Int J Oncol (2013) 0.81
Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance. Cancer Med (2015) 0.81
Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene. Mol Clin Oncol (2014) 0.81
Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents. Ann Transl Med (2015) 0.81
EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors of non small cell lung cancer: a clue to overcoming resistance. Transl Lung Cancer Res (2013) 0.79
Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis. Oncotarget (2016) 0.79
EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression. Front Oncol (2014) 0.79
Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma. World J Clin Oncol (2013) 0.79
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol (2017) 0.79
Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer. Sci Rep (2016) 0.78
Disparate survival trends in histologic subtypes of metastatic non-small cell lung cancer: a population-based analysis. Am J Cancer Res (2015) 0.78
Sequential treatment of tyrosine kinase inhibitor and platinum-based doublet chemotherapy on EGFR mutant non-small cell lung cancer: a meta-analysis of randomized controlled clinical trials. Onco Targets Ther (2017) 0.77
Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. Front Med (Lausanne) (2017) 0.77
Is epidermal growth factor receptor tyrosine kinase inhibitor in combination with cytotoxic chemotherapy a better treatment option for patients with EGFR-mutated non-small-cell lung cancer? Transl Lung Cancer Res (2016) 0.76
Important factors for achieving survival of five years or more in non-small cell lung cancer patients with distant metastasis. Oncol Lett (2014) 0.76
Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis. Onco Targets Ther (2016) 0.76
miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance. Ecancermedicalscience (2015) 0.76
Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma. Oncotarget (2016) 0.75
EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10). Cancer Manag Res (2016) 0.75
EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression. Medicine (Baltimore) (2016) 0.75
Efficacy of third-line pemetrexed monotherapy versus pemetrexed combination with bevacizumab in patients with advanced EGFR mutation-positive lung adenocarcinoma. Chin J Cancer Res (2014) 0.75
Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context. Ther Clin Risk Manag (2017) 0.75
Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond. Lung Cancer (Auckl) (2013) 0.75
Afatinib in lung cancer harboring EGFR mutation in the LUX-Lung trials: six plus three is greater than seven? Transl Lung Cancer Res (2016) 0.75
Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts. Oncotarget (2016) 0.75
Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma. Int J Clin Exp Pathol (2015) 0.75
Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis. Onco Targets Ther (2017) 0.75
Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitors. J Thorac Dis (2016) 0.75
Comparing overall survival between first generation EGFR-TKIs and chemotherapy in lung cancer patients with Del19/L858R. Chin J Cancer Res (2016) 0.75
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat Commun (2017) 0.75
Clinician Perspectives on Current Issues in Lung Cancer Drug Development. J Thorac Oncol (2016) 0.75
Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer. Int J Clin Oncol (2016) 0.75
Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients. Br J Cancer (2016) 0.75
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib. Front Oncol (2017) 0.75
Durable complete remission of poor performance status metastatic lung adenocarcinoma patient treated with second-line erlotinib: a case report. Onco Targets Ther (2017) 0.75
Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status. Sci Rep (2017) 0.75
Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations. Int J Clin Oncol (2015) 0.75
Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer. Target Oncol (2017) 0.75
EGFR Mutation Testing of non-squamous NSCLC: Impact and Uptake during Implementation of Testing Guidelines in a Population-Based Registry Cohort from Northern New Zealand. Target Oncol (2017) 0.75
The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature (1997) 33.47
Essential Bacillus subtilis genes. Proc Natl Acad Sci U S A (2003) 14.01
Mammalian Cry1 and Cry2 are essential for maintenance of circadian rhythms. Nature (1999) 7.86
Morphogenesis and renewal of hair follicles from adult multipotent stem cells. Cell (2001) 6.37
Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature (1999) 6.23
Evidence for circulating bone marrow-derived endothelial cells. Blood (1998) 6.15
The 5'-terminal sequence of the hepatitis C virus genome. Jpn J Exp Med (1990) 5.46
A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochem Biophys Res Commun (1997) 5.25
Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet (1995) 5.03
T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1 beta. Nature (1993) 4.57
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer (2006) 4.46
Crystal structure of human serum albumin at 2.5 A resolution. Protein Eng (1999) 4.37
Standard steroid treatment for autoimmune pancreatitis. Gut (2009) 4.33
Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analyses. Science (1971) 4.27
High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol Sci (2001) 4.02
Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci U S A (1997) 3.88
Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature (1989) 3.80
Elucidation of the Erwinia uredovora carotenoid biosynthetic pathway by functional analysis of gene products expressed in Escherichia coli. J Bacteriol (1990) 3.78
Detection of serum hepatitis B virus DNA in patients with chronic hepatitis using the polymerase chain reaction assay. Proc Natl Acad Sci U S A (1989) 3.67
Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci U S A (1990) 3.52
Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev (2001) 3.43
Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature (1993) 3.42
Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology (2000) 3.42
Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev Cell (2001) 3.29
Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology (1992) 3.22
A novel putative tyrosine kinase receptor encoded by the eph gene. Science (1987) 3.10
Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat Genet (1999) 3.07
Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res (1993) 3.05
Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci U S A (1998) 2.96
Location of stem cells of human hair follicles by clonal analysis. Cell (1994) 2.96
Energy release in the solar corona from spatially resolved magnetic braids. Nature (2013) 2.90
Bni1p implicated in cytoskeletal control is a putative target of Rho1p small GTP binding protein in Saccharomyces cerevisiae. EMBO J (1996) 2.87
Antigenic drift of equine infectious anemia virus in chronically infected horses. Arch Gesamte Virusforsch (1973) 2.86
Rom1p and Rom2p are GDP/GTP exchange proteins (GEPs) for the Rho1p small GTP binding protein in Saccharomyces cerevisiae. EMBO J (1996) 2.76
Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res (1999) 2.74
Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5'-noncoding region. Jpn J Exp Med (1990) 2.72
Expression of immunoreactive E-cadherin adhesion molecules in human cancers. Am J Pathol (1991) 2.71
Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci U S A (1994) 2.64
Tumor angiogenesis in human lung adenocarcinoma. Cancer (1994) 2.59
High-resolution endoscopic imaging of the GI tract using optical coherence tomography. Gastrointest Endosc (2000) 2.53
Giant Rashba-type spin splitting in bulk BiTeI. Nat Mater (2011) 2.49
Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature (1997) 2.46
Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab (2000) 2.43
cDNA cloning and tissue-specific expression of a novel basic helix-loop-helix/PAS factor (Arnt2) with close sequence similarity to the aryl hydrocarbon receptor nuclear translocator (Arnt). Mol Cell Biol (1996) 2.42
Location of functional regions of acetylcholine receptor alpha-subunit by site-directed mutagenesis. Nature (1985) 2.40
A woman who trembled, then had chorea. Lancet (1998) 2.40
Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway. Oncogene (2006) 2.36
DBTBS: a database of Bacillus subtilis promoters and transcription factors. Nucleic Acids Res (2001) 2.35
Non-A, non-B hepatitis specific antibodies directed at host-derived epitope: implication for an autoimmune process. Lancet (1990) 2.35
Evaluation and characterization of catabolite-responsive elements (cre) of Bacillus subtilis. Nucleic Acids Res (2000) 2.35
Serum undercarboxylated osteocalcin levels are inversely associated with glycemic status and insulin resistance in an elderly Japanese male population: Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Study. Osteoporos Int (2011) 2.32
Distribution of saccharide residues on membrane fragments from a myeloma-cell homogenate: its implications for membrane biogenesis. Proc Natl Acad Sci U S A (1972) 2.29
RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region. J Biol Chem (1998) 2.29
The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. J Biol Chem (2001) 2.29
Combined transcriptome and proteome analysis as a powerful approach to study genes under glucose repression in Bacillus subtilis. Nucleic Acids Res (2001) 2.28
Purification and properties of chromosomally mediated beta-lactamase from Citrobacter freundii GN7391. J Gen Microbiol (1980) 2.28
Exploring postinfarction reentrant ventricular tachycardia with entrainment mapping. J Am Coll Cardiol (1997) 2.27
Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett (1994) 2.27
Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology (1994) 2.26
Augmentation of Valpha14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J Exp Med (2000) 2.25
Location and properties of glucose dehydrogenase in sporulating cells and spores of Bacillus subtilis. J Bacteriol (1977) 2.24
Organization and transcription of the gluconate operon, gnt, of Bacillus subtilis. J Biol Chem (1986) 2.23
Identification of IQGAP as a putative target for the small GTPases, Cdc42 and Rac1. J Biol Chem (1996) 2.22
The essential two-component regulatory system encoded by yycF and yycG modulates expression of the ftsAZ operon in Bacillus subtilis. Microbiology (2000) 2.21
Identification of a new imprinted gene, Rian, on mouse chromosome 12 by fluorescent differential display screening. J Biochem (2001) 2.19
Overexpression of the robA gene increases organic solvent tolerance and multiple antibiotic and heavy metal ion resistance in Escherichia coli. Appl Environ Microbiol (1995) 2.18
Covalent structure of a group-specific protease from rat small intestine. Appendix: crystallographic data for a group specific protease from rat intestine. Biochemistry (1978) 2.17
Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett (1994) 2.17
Congenital Minamata disease: intrauterine methylmercury poisoning. Teratology (1978) 2.15
SecD is involved in the release of translocated secretory proteins from the cytoplasmic membrane of Escherichia coli. EMBO J (1993) 2.14
DNA microarray analysis of Bacillus subtilis DegU, ComA and PhoP regulons: an approach to comprehensive analysis of B.subtilis two-component regulatory systems. Nucleic Acids Res (2001) 2.13
Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology (1991) 2.13
Role of gob-5 in mucus overproduction and airway hyperresponsiveness in asthma. Proc Natl Acad Sci U S A (2001) 2.12
Two E-rosette-forming lymphoid cell lines. Int J Cancer (1978) 2.09
Enhancement of rice canopy carbon gain by elevated CO(2) is sensitive to growth stage and leaf nitrogen concentration. New Phytol (2006) 2.09
Comparison of various submucosal injection solutions for maintaining mucosal elevation during endoscopic mucosal resection. Endoscopy (2004) 2.08
An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care (1998) 2.08
Promotion of spontaneous diabetes in non-obese diabetes-prone mice by cyclophosphamide. Diabetologia (1984) 2.07
Derepression of arylsulfatase synthesis in Aerobacter aerogenes by tyramine. J Bacteriol (1973) 2.07
Classification and Structural Comparison of Full-Length cDNAs for Pathogenesis-Related Proteins. Plant Physiol (1987) 2.06
Two mouse piwi-related genes: miwi and mili. Mech Dev (2001) 2.05
Cell cycle regulation of hepatitis C virus internal ribosomal entry site-directed translation. Gastroenterology (2000) 2.05
Detection of serum hepatitis C virus RNA. Lancet (1990) 2.05
Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology (1999) 2.05
New method of deep brain stimulation therapy with two electrodes implanted in parallel and side by side. J Neurosurg (2001) 2.04
Insulin resistance in mitochondrial gene mutation. Diabetes Care (1994) 2.03
Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ (2008) 2.03
O-alkyl-l-homoserines: three new amino acids formed from alcohols by Corynebacterium ethanolaminophilum sp. nov. Biochem Biophys Res Commun (1967) 2.02
Catabolite repression and derepression of arylsulfatase synthesis in Klebsiella aerogenes. J Bacteriol (1974) 2.01
Reconstitution of tubular myelin from synthetic lipids and proteins associated with pig pulmonary surfactant. Am Rev Respir Dis (1989) 2.00
DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53. Proc Natl Acad Sci U S A (2001) 2.00
Location of a delta-subunit region determining ion transport through the acetylcholine receptor channel. Nature (1987) 1.99
Organic solvent tolerance and antibiotic resistance increased by overexpression of marA in Escherichia coli. Appl Environ Microbiol (1997) 1.98
Glue embolization for gastroduodenal ulcer bleeding: contribution to hemodynamics and healing process. Acta Radiol (2013) 1.98